RNA - Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy.
As of Nov 13, 2026: spot at $7.66, max pain $70.00, GEX (assumed dealer book) -$0 of delta per 1% move.
Exposures are the assumed dealer book over the expirations within 30 days of the session, or the first four when none are (3 expirations, through Jan 21, 2028), as of Nov 13, 2026. Assumes dealers are long the calls and short the puts, a share p of open interest each - here 100% of open interest (the GEX page sets the share). A date without a stored exposure is a gap; a value marked * is partial, averaged over fewer days, or may include contracts expiring that day or of an unreadable expiration: its reason is printed beside it.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $128.5M
- Beta
- 0.37
- 52-Week Range
- 7.47-16.77
- CEO
- Kathleen Gallagher
- Employees
- 511
- IPO Date
- Feb 27, 2026
- Exchange
- NASDAQ
What RNA Looks Like to Options Traders Today
the assumed dealer book's GEX is negative (-$0 of delta per 1% move): its hedging goes with the trend, amplifying realized volatility and accelerating directional moves where real dealers are positioned like the book.
What This Page Covers
The RNA overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked RNA overview questions
- What is RNA?
- RNA is the ticker symbol for Atrium Therapeutics, Inc., a listed security. Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Listed on NASDAQ. RNA is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the RNA options snapshot look like today?
- As of Nov 13, 2026, the RNA options snapshot shows spot at $7.66, max pain $70.00, GEX (assumed dealer book) -$0 of delta per 1% move. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, the assumed dealer book's gamma exposure and the put-minus-call delta balance, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are RNA's key statistics?
- Atrium Therapeutics, Inc. (RNA) carries a market capitalization of $128.5M, beta of 0.37 relative to the broader market, 52-week range of 7.47-16.77. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does RNA belong to?
- Atrium Therapeutics, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare RNA's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the RNA data on this page?
- The options snapshot above is dated Nov 13, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, twice-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).